Home > Insider Trading > Filing (0001062993-25-004809)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1478320	Adaptive Biotechnologies Corp	ADPT	Biological Products, (No Disgnostic Substances) (2836)	270907024

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1780649	M Chad Robins	C/O Adaptive Biotechnologies Corporation 1165 Eastlake Avenue East Seattle WA 98109	Ceo And Chairman	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-03-04	355,000	$0.00	2,931,701	No	4	A	Direct
Common Stock	Disposition	2025-03-05	81,206	$6.98	2,850,495	No	4	S	Direct
Common Stock	Disposition	2025-03-05	36,145	$6.99	2,814,350	No	4	S	Direct
Common Stock	Acquisiton	2025-03-05	247,117	$0.00	3,061,467	No	4	A	Direct
Common Stock	Disposition	2025-03-06	102,218	$7.64	2,959,249	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	A	Direct
No	4	S	Direct

Footnotes

This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 4, 2022, with respect to the three-year period ending on March 4, 2025. The issuer certified the achievement of the performance goals on March 5, 2025. The performance share units vested on March 5, 2025.
This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance share units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.